Articles by Malin Sternby Eilard in JoVE
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma Ilan Ben-Shabat1,4, Christoffer Hansson2,4, Malin Sternby Eilard3,4, Christian Cahlin3,4, Magnus Rizell3,4, Per Lindnér3,4, Jan Mattsson1,4, Roger Olofsson Bagge1,4 1Department of Surgery, Institute of Clinical Sciences, 2Department of Thoracic Surgery, Institute of Clinical Sciences, 3Transplant Institute, Institute of Clinical Sciences, 4Sahlgrenska University Hospital, Sahlgrenska Academy at the University of Gothenburg Here, we present a protocol how to perform an isolated liver perfusion (IHP) with melphalan and we also discuss IHP as a treatment option for liver metastases of uveal melanoma.
Other articles by Malin Sternby Eilard on PubMed
Isolated Hepatic Perfusion As a Treatment for Uveal Melanoma Liver Metastases (the SCANDIUM Trial): Study Protocol for a Randomized Controlled Trial Trials. 2014 | Pubmed ID: 25106493 Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the liver being the most common site for metastases. The median survival for patients with liver metastases is between 6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared with a historic control group consisting of the longest surviving patients in Sweden during the same time period (26 versus 12 months).